While leading cytokine therapeutic developers are using next-generation cytokine engineering technologies to tackle enduring efficacy and toxicity challenges to take their...

The ADC payload landscape is shifting rapidly. Driven by clinical successes of lower potency topoisomerase I inhibitors and as payloads that elicit novel modes of action...